Representative Matters
REFERENZMANDATE
代表事项
M&A and Strategic Partnerships
- Represented financial advisor in Merck’s 2021 definitive agreement to acquire Acceleron Pharma Inc. ($11.5 billion)
- Shields Health Solutions, its management team and UMass in connection with Walgreens Boots Alliance’s 2021 majority investment in Shields ($970 million)
- Trillium Therapeutics in its 2021 definitive agreement to be acquired by Pfizer ($2.26 billion)
- Valo Health in its announced 2021 business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
- Cerevel Therapeutics in its 2021 business combination with ARYA Sciences Acquisition Corp II ($440 million)
- Represented financial advisor in Pandion Therapeutics’ 2021 definitive sale to Merck ($1.85 billion)
- KIND in its 2020 definitive acquisition by Mars, Incorporated ($5 billion)
- MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
- Represented financial advisor in Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
- Represented financial advisor in Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
- Represented financial advisor in Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
- AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
- Represented financial advisor in Arqule’s 2020 acquisition by Merck ($2.7 billion)
- Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
- Twilio in its 2019 acquisition of SendGrid ($3 billion)
- Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
- Keryx in its 2018 merger with Akebia ($1.3 billion)
- Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
- PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
- PAREXEL in its 2017 sale to Pamplona ($5 billion)
- AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
- The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion)
- The 2016 private company sale of Stemcentrix to Abbvie ($5.8 billion)
- Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
- Xoom in its 2015 sale to PayPal ($1 billion)
- Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
- Eloqua in its 2012 sale to Oracle ($1 billion)
Financings and Public Offerings
- Moderna in connection with its
- 2020 follow-on public offerings ($500 million in March and $1.34 billion in May)
- 2018 record biotech initial public offering ($604 million)
- 2018 private financing ($500 million)
- 2016 private financing ($474 million)
-
Laronde in its 2021 Series B financing ($440 million)
- Cerevel Therapeutics in its 2021 underwritten public offering ($350 million)
- Repertoire Immune Medicines in its 2021 Series B financing ($189 million)
- Aura Biosciences in its 2021 private financing ($80 million)
- Rubius Therapeutics in connection with its
- 2021 underwritten public offering ($200 million)
- 2018 initial public offering ($277.3 million)
- 2018 crossover financing ($100 million)
- 2017 private financing ($120 million)
- Valo Health in its 2021 Series B ($300 million)
- Tessera Therapeutics in its 2021 Series B financing ($230 million)
Special Committee Representations
- Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including the Transaction Committee of Sprint in Sprint Corporation’s award winning merger with T-Mobile US, Inc. (April 2020) and most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio (March 2021).
COMMUNITY AND PRO BONO ACTIVITIES
Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.
Mr. Cable leads the firm’s pro bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors. Mr. Cable is also a member of the Goodwin pro bono team advising the Boston Red Sox Foundation on Board and governance matters.
Publications and Media Mentions
Mr. Cable has for more than a decade annually taught aspiring MBAs about the practical aspects of fiduciary duty and Board responsibility in the context of public company mergers and acquisitions, at MIT's Sloan School of Management, the Tuck School of Business Administration at Dartmouth College and the Wharton School at the University of Pennsylvania. Some of his recent speaking engagements and presentations include:
- “Fireside Chat with Noubar Afeyan,” a fireside chat with industry luminary, Noubar Afeyan, Chairman and Co-Founder of Moderna (2021 Goodwin +KPMG @ JPMorgan Symposium)
- “Healthcare Trends – Trends in the Office of the GC,” covers the ways in which life sciences and healthcare GCs are managing outside counsel and legal costs, leveraging new technologies to improve workflow and knowledge management, and remaining vigilant against persistent and rapidly shifting risks through the lens of the pandemic (2020 Goodwin Webinar)
- “M&A in 2020 and 2021,” examines the status of the current M&A market trends and potential volatility (2020 Executive Insights, Board Leaders)
- “Take-Private Transactions,” a webinar aimed at getting ahead of the recovery curve as we discussed how to navigate take-private transactions from both the buy- and sell-side perspective (2020 Goodwin’s What’s Next Webinar Series)
- “What Happens When Big Pharma Comes Knocking?,” an interactive presentation that takes participants through a public company sale process in only 60 minutes (2020 Goodwin + KPMG Symposium @ JP Morgan)
- “Responsibility to Stakeholders versus Shareholders – Part 2,” examines the recent announcement that shifts the focus of board responsibility regarding governance from shareholders to stakeholders (2019 Executive Insights, Board Leaders)
- “Responsibility to Stakeholders versus Shareholders – Part 1,” examines the recent announcement that shifts the focus of board responsibility regarding governance from shareholders to stakeholders (2019 Executive Insights, Board Leaders)
- “Governance Grab Bag: Speak for Yourself,” examines the advisability in different contexts of direct communication between a Director and a stockholder (2018 Directors Forum)
- “Governance Grab Bag: Social Studies,” delves into a Merger of Equals and the “non-economic” or social issues that are frequently the subject of negotiation in a MOE (2018 Directors Forum)
- “Governance Grab Bag: We’ve Got Bigger Problems,” decodes a Board Evaluation process and weighs the issues uncovered (2018 Directors Forum)
- “Comparing an Apple, an Orange and a Pear,” features a hypothetical public company board discussion comparing an all cash strategic M&A proposal against both an all stock strategic transaction and a private equity-backed go private transaction (2017 Directors Forum)
- “The Directors Challenge--A Lightning Round,” features a series of boardroom “crisis” case studies presented in ‘lightning rounds’ (2016 Directors Forum)
- “Sitting at the Head of the Table,” a roundtable discussion with three Board chairpersons addressing strategy, shareholder outreach and the relationship between a Board chair and the CEO (2015 Directors Forum)
- “A Foundational Transaction,” a discussion of how Boards should approach strategic partnerships when a majority stake acquisition is proposed (2015 Directors Forum)
- “Boom or Bust: Opportunities and Risk in M&A,” a panel with leading investment bankers to discuss global dealmaking in sectors including biopharma, technology and energy as well as the increasing role of activist shareholders (2015 Milken Global Conference)
Mr. Cable is a frequent speaker on matters related to corporate governance, mergers and acquisitions, corporate finance and securities law. Some of his recent newsworthy quotes and publication features include:
- “Legal Deal Work Zooms Into 2021,” discusses ways in which deal parties have visibility on how companies are responding to the pandemic and practitioners have a good handle on what parameters they need to look at when conducting due diligence (2021 Mergermarket)
- “5 Trends In Biotech Dealmaking To Watch In 2021,” covers public M&A and corporate governance trends (2021 BioPharma Dive)
- “Tech M+A To Drive Busier 2021 For Deal Lawyers After Tough Year,” discusses the ways in which M&A activity bounced back in the latter half of 2020 and highlights trends to watch in the year ahead (2021 Bloomberg Law)
- “Pandemic, Democratic Wins Leave Drug Industry At Crossroads,” spotlights that M&A deal activity rose to a borderline fever pitch by the end of 2020 (2021 Bloomberg)
- “Drinks With The Deal Podcast: Goodwin Procter's Stuart Cable,” discusses Goodwin’s Life Sciences team and the ways in which Goodwin services biotech companies ranging in size from startups to multibillion-dollar public companies (2021 The Deal)
